- Home
- PRT vs RNXT Comparison
PRT vs RNXT Comparison
Compare PRT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- RNXT
- Stock Information
- Founded
- PRT 2017
- RNXT 2012
- Country
- PRT United States
- RNXT United States
- Employees
- PRT N/A
- RNXT N/A
- Industry
- PRT Oil & Gas Production
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- PRT Energy
- RNXT Health Care
- Exchange
- PRT Nasdaq
- RNXT Nasdaq
- Market Cap
- PRT 48.2M
- RNXT 44.6M
- IPO Year
- PRT N/A
- RNXT 2021
- Fundamental
- Price
- PRT $3.98
- RNXT $0.96
- Analyst Decision
- PRT
- RNXT Strong Buy
- Analyst Count
- PRT 0
- RNXT 2
- Target Price
- PRT N/A
- RNXT $7.25
- AVG Volume (30 Days)
- PRT 28.4K
- RNXT 193.1K
- Earning Date
- PRT 08-13-2025
- RNXT 08-14-2025
- Dividend Yield
- PRT 10.94%
- RNXT N/A
- EPS Growth
- PRT 1.16
- RNXT N/A
- EPS
- PRT 0.44
- RNXT N/A
- Revenue
- PRT $6,314,770.00
- RNXT $662,000.00
- Revenue This Year
- PRT N/A
- RNXT $3,104.65
- Revenue Next Year
- PRT N/A
- RNXT $301.89
- P/E Ratio
- PRT $9.04
- RNXT N/A
- Revenue Growth
- PRT 1.82
- RNXT N/A
- 52 Week Low
- PRT $3.26
- RNXT $0.75
- 52 Week High
- PRT $4.63
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- PRT 45.31
- RNXT 30.04
- Support Level
- PRT $3.95
- RNXT $1.23
- Resistance Level
- PRT $4.05
- RNXT $1.37
- Average True Range (ATR)
- PRT 0.07
- RNXT 0.09
- MACD
- PRT -0.01
- RNXT -0.01
- Stochastic Oscillator
- PRT 27.27
- RNXT 11.77
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.